Insider Selling: Sera Prognostics (NASDAQ:SERA) Director Sells 3,899 Shares of Stock

Key Points

• Sera Prognostics Director Sandra Aj Lawrence sold 3,899 shares of stock for a total of $11,891.95, reducing her ownership by 17.17% to 18,814 shares.
• The company reported a net margin of -30,306.48% and a revenue of $0.02 million in its latest quarterly earnings, beating expectations but reflecting ongoing financial challenges.
• Wall Street analyst Wall Street Zen downgraded Sera Prognostics from a "hold" to a "sell" rating amid ongoing struggles in stock performance and earnings.

Sera Prognostics, Inc. (NASDAQ:SERA - Get Free Report) Director Sandra Aj Lawrence sold 3,899 shares of the firm's stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $3.05, for a total transaction of $11,891.95. Following the completion of the sale, the director directly owned 18,814 shares in the company, valued at $57,382.70. This represents a 17.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Sera Prognostics Price Performance

SERA stock traded down $0.07 during midday trading on Tuesday, reaching $3.10. The company had a trading volume of 74,640 shares, compared to its average volume of 104,642. Sera Prognostics, Inc. has a 1 year low of $1.37 and a 1 year high of $9.13. The company has a market capitalization of $116.78 million, a P/E ratio of -3.65 and a beta of 1.00. The firm has a 50-day moving average price of $2.77 and a 200-day moving average price of $2.88.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.05. Sera Prognostics had a negative net margin of 30,306.48% and a negative return on equity of 45.86%. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.05 million. On average, equities analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current year.

Institutional Trading of Sera Prognostics

Several institutional investors have recently added to or reduced their stakes in SERA. Wells Fargo & Company MN grew its stake in shares of Sera Prognostics by 55.2% during the fourth quarter. Wells Fargo & Company MN now owns 13,192 shares of the company's stock valued at $107,000 after buying an additional 4,691 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in Sera Prognostics during the 4th quarter worth approximately $93,000. Northern Trust Corp grew its position in Sera Prognostics by 11.8% during the 4th quarter. Northern Trust Corp now owns 272,860 shares of the company's stock worth $2,221,000 after acquiring an additional 28,863 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Sera Prognostics in the 4th quarter worth approximately $28,000. Finally, Bank of America Corp DE lifted its position in Sera Prognostics by 38.9% in the fourth quarter. Bank of America Corp DE now owns 27,880 shares of the company's stock valued at $227,000 after purchasing an additional 7,813 shares during the last quarter. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut Sera Prognostics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.